This review proposes that K2's superior adverse outcome prevalence is due, at the least partially, to distinctive JWH-018 metabolite activity for the cannabinoid 1 receptor (CB1R), and indicates that metabolites of most medicine, but not the carboxy metabolite, retain in vitro and in vivo exercise at CB1Rs. Remaining linked to https://alexisumdsg.ageeksblog.com/30330448/not-known-details-about-mam-2201